Published in J Transl Med on January 23, 2007
Serum markers of hepatocellular carcinoma. Dig Dis Sci (2010) 1.76
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
A review on laboratory liver function tests. Pan Afr Med J (2009) 1.04
Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One (2014) 0.97
Hepatocellular carcinoma: Review of disease and tumor biomarkers. World J Hepatol (2016) 0.94
Circulating tumor cells measurements in hepatocellular carcinoma. Int J Hepatol (2012) 0.91
Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma. Exp Ther Med (2012) 0.88
Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. Yale J Biol Med (2011) 0.88
Expression and prognostic significance of cancer-testis antigens (CTA) in intrahepatic cholagiocarcinoma. J Exp Clin Cancer Res (2011) 0.86
Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol (2012) 0.85
Spermatogenesis associated retrogenes are expressed in the human ovary and ovarian cancers. PLoS One (2009) 0.83
Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma? J Zhejiang Univ Sci B (2007) 0.82
Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol (2009) 0.81
The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med (2008) 0.81
XAGE-1b expression is associated with the diagnosis and early recurrence of hepatocellular carcinoma. Mol Clin Oncol (2014) 0.77
Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma. BMC Res Notes (2012) 0.77
Biomarkers for Hepatocellular Carcinoma. Biomark Cancer (2017) 0.75
Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65
Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science (1992) 24.32
Hepatocellular carcinoma. Lancet (2003) 22.54
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer (2006) 10.05
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature (1990) 6.59
The cancer/testis genes: review, standardization, and commentary. Cancer Immun (2004) 4.78
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 4.63
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology (2003) 2.90
Immunological aspects of malignant disease. Lancet (1967) 2.66
Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res (1968) 2.28
Angiogenesis and hepatocellular carcinoma. J Hepatol (2004) 2.25
Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology (2002) 2.13
Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology (2004) 2.08
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology (2003) 2.05
Functional genomics of hepatocellular carcinoma. Hepatology (2006) 2.02
Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol (2005) 1.87
Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol (2006) 1.82
Genome-scale profiling of gene expression in hepatocellular carcinoma: classification, survival prediction, and identification of therapeutic targets. Gastroenterology (2004) 1.71
Molecular biology and evolution. Can genes explain biological complexity? Science (2001) 1.71
Common cancer biomarkers. Cancer Res (2006) 1.56
Hepatocellular carcinoma. Curr Opin Gastroenterol (2006) 1.50
Quantitative assessment of hTERT mRNA expression in dysplastic nodules of HBV-related hepatocarcinogenesis. Am J Gastroenterol (2006) 1.48
Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod Pathol (2003) 1.45
Interleukin-8 serum levels in patients with hepatocellular carcinoma: correlations with clinicopathological features and prognosis. Clin Cancer Res (2003) 1.41
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: Impact on neovascularization and survival. World J Gastroenterol (2005) 1.36
Hepatocellular carcinoma. An overview. Ann Hepatol (2006) 1.29
Detection of alpha-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: a possible predictor of metastatic hepatocellular carcinoma. Hepatology (1994) 1.26
Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach. Proteomics (2006) 1.25
Serum alpha-L-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma? Hepatology (1984) 1.19
Serum markers of hepatocellular carcinoma. Semin Liver Dis (2006) 1.17
Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol (2003) 1.17
Serological markers of liver cancer. Best Pract Res Clin Gastroenterol (2005) 1.17
Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett (2005) 1.16
Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer (2005) 1.16
Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn (2004) 1.16
Serum alpha-L-fucosidase. A useful marker in the diagnosis of hepatocellular carcinoma. Cancer (1992) 1.10
Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br J Cancer (2003) 1.10
Histopathology of liver cancers. Best Pract Res Clin Gastroenterol (2005) 1.09
Transforming growth factor-beta1 as a useful serologic marker of small hepatocellular carcinoma. Cancer (2002) 1.09
Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol (2005) 1.09
Cancer immunotherapy: the past, the present and the future. Immunol Cell Biol (2003) 1.06
Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol (1996) 1.04
Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol (2005) 1.02
Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol (2005) 1.01
Cancer: looking for simplicity and finding complexity. Cancer Cell Int (2006) 1.01
Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol (2002) 1.01
Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun (2002) 0.99
Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem (2004) 0.98
Liver cancer on the rise. Ann Intern Med (2005) 0.97
The complexity of anatomical systems. Theor Biol Med Model (2005) 0.96
Cancer immunotherapy: avoiding the road to perdition. J Transl Med (2004) 0.95
TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer (2005) 0.94
Peptide binding to MHC class I molecules: implications for antigenic peptide prediction. Immunol Res (1995) 0.94
Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling. Semin Liver Dis (2006) 0.94
Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer (2006) 0.93
Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis (2006) 0.91
Tumor-associated antigens: from discovery to immunity. Int Rev Immunol (2003) 0.91
Apoptosis in the liver and its role in hepatocarcinogenesis. Cell Biol Toxicol (1997) 0.90
Reductionism. The ends of understanding. Nature (1997) 0.88
Differential regulation of gamma-glutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta (2001) 0.87
Proteomics in the diagnosis of hepatocellular carcinoma: focus on high risk hepatitis B and C patients. Anticancer Res (2006) 0.87
HCA587 antigen expression in normal tissues and cancers: correlation with tumor differentiation in hepatocellular carcinoma. Lab Invest (2003) 0.87
Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol (2004) 0.86
Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs (2005) 0.85
Role of AFP mRNA expression in peripheral blood as a predictor for postsurgical recurrence of hepatocellular carcinoma: a systematic review and meta-analysis. World J Gastroenterol (2005) 0.85
Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver. Toxicol Pathol (2005) 0.85
Expression of vascular endothelial growth factor in hepatocellular carcinoma and the surrounding liver and correlation with MRI findings. AJR Am J Roentgenol (2005) 0.84
[Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma]. Ai Zheng (2005) 0.84
Value of the serum alpha-L-fucosidase activity in the diagnosis of colorectal cancer. Oncology (2000) 0.84
Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model (2006) 0.84
Heterogeneity in gamma-glutamyltransferase mRNA expression and glycan structures. Search for tumor-specific variants in human liver metastases and colon carcinoma cells. Biochim Biophys Acta (2003) 0.82
Expression of cancer-testis antigen (CTA) in tumor tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci (2006) 0.82
Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma? World J Gastroenterol (2003) 0.81
Second trimester serum markers. Semin Perinatol (2005) 0.81
[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma]. Zhonghua Bing Li Xue Za Zhi (2005) 0.81
Serum alpha L-fucosidase enzyme activity in ovarian and other female genital tract tumors. Int J Gynaecol Obstet (1996) 0.81
Expression of cancer testis antigens in pancreatic carcinoma cell lines, pancreatic adenocarcinoma and chronic pancreatitis. Int J Cancer (2004) 0.80
[Detection of serum tumor supplied group of factors and its clinical significance]. Ai Zheng (2002) 0.80
Cellular distribution of telomerase reverse transcriptase in human hepatocellular carcinoma. J Gastroenterol Hepatol (2003) 0.80
Hepatocellular carcinoma in a rural population at risk. Anticancer Res (1992) 0.80
Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc) (2006) 0.80
Modulation of human telomerase reverse transcriptase in hepatocellular carcinoma. World J Gastroenterol (2004) 0.79
Complexity and cancer. Gastroenterology (2004) 0.79
[Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis]. Nan Fang Yi Ke Da Xue Xue Bao (2006) 0.77
Purification and characterization of alpha-L-fucosidase from human primary hepatocarcinoma tissue. World J Gastroenterol (2006) 0.77
Role of vascular endothelial growth factor on the invasive potential of hepatocellular carcinoma. J Hepatol (2004) 0.76
Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci (2008) 2.26
FAM20: an evolutionarily conserved family of secreted proteins expressed in hematopoietic cells. BMC Genomics (2005) 1.70
Expression of sperm protein 17 (Sp17) in ovarian cancer. Int J Cancer (2004) 1.70
An ethanol protocol to prevent alcohol withdrawal syndrome. J Am Coll Surg (2006) 1.55
Future directions in training surgical residents to perform endoscopic examinations. Am Surg (2008) 1.42
Local biological factors that influence amputations in diabetic patients. South Med J (2007) 1.39
Reinforcement does not necessarily reduce the rate of staple line leaks after sleeve gastrectomy. A review of the literature and clinical experiences. Obes Surg (2008) 1.36
Ileal transposition controls diabetes as well as modified duodenal jejunal bypass with better lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1. Ann Surg (2008) 1.25
Nanotechnology and human health: risks and benefits. J Appl Toxicol (2010) 1.15
Identification of AKAP-4 as a new cancer/testis antigen for detection and immunotherapy of prostate cancer. Prostate (2011) 1.11
AKAP-4: a novel cancer testis antigen for multiple myeloma. Br J Haematol (2008) 1.11
A comparison of anterior and posterior approaches for the surgical treatment of pancreatic pseudocyst using laparoscopic cystogastrostomy. J Laparoendosc Adv Surg Tech A (2005) 1.08
Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. Int Rev Immunol (2011) 1.06
p53-Dependent anticancer effects of leptomycin B on lung adenocarcinoma. Cancer Chemother Pharmacol (2010) 1.06
Cancer: looking for simplicity and finding complexity. Cancer Cell Int (2006) 1.01
Hepatoid carcinoma of the pancreas: a case report. Chin Med J (Engl) (2007) 0.98
Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood (2002) 0.98
Sperm protein 17 is expressed in human somatic ciliated epithelia. J Histochem Cytochem (2004) 0.96
The complexity of anatomical systems. Theor Biol Med Model (2005) 0.96
Mapping gene expression patterns during myeloid differentiation using the EML hematopoietic progenitor cell line. Exp Hematol (2002) 0.94
Notch1 regulates chemotaxis and proliferation by controlling the CC-chemokine receptors 5 and 9 in T cell acute lymphoblastic leukaemia. J Pathol (2011) 0.93
Sperm protein 17 is expressed in human nervous system tumours. BMC Cancer (2006) 0.93
Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol (2003) 0.93
Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis (2009) 0.92
Laparoscopic splenectomy in blunt trauma. JSLS (2007) 0.92
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Quantitative evaluation and modeling of two-dimensional neovascular network complexity: the surface fractal dimension. BMC Cancer (2005) 0.92
Fractal analysis of two-dimensional vascularity in primary prostate cancer and surrounding non-tumoral parenchyma. Pathol Res Pract (2009) 0.91
Dendritic cell vaccination against ovarian cancer--tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther (2011) 0.90
Infection, replication, and cytopathology of human papillomavirus type 31 in trophoblasts. Virology (2003) 0.89
Calcitonin increases invasiveness of prostate cancer cells: role for cyclic AMP-dependent protein kinase A in calcitonin action. Int J Cancer (2005) 0.89
Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors. In Vitro Cell Dev Biol Anim (2006) 0.89
Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer. PLoS One (2010) 0.89
Levels of specific peptide-HLA class I complex predicts tumor cell susceptibility to CTL killing. J Immunol (2006) 0.89
Analysis of the results of sleeve gastrectomy for morbid obesity and the role of ghrelin. Surg Today (2008) 0.89
Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol (2007) 0.89
Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol (2008) 0.88
Fractal dimension rectified meter for quantification of liver fibrosis and other irregular microscopic objects. Anal Quant Cytol Histol (2003) 0.88
Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis (2008) 0.87
Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes. J Immunol Methods (2006) 0.87
Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst's exponent. World J Gastroenterol (2006) 0.87
Immunolocalization of sperm protein 17 in human testis and ejaculated spermatozoa. J Histochem Cytochem (2003) 0.87
Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma. PLoS One (2011) 0.86
Notch-ing from T-cell to B-cell lymphoid malignancies. Cancer Lett (2011) 0.85
Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling. Clin Exp Metastasis (2007) 0.85
Biological treatment for liver tumor and new potential biomarkers. Dig Dis Sci (2007) 0.85
Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. PLoS One (2012) 0.85
The multiple faces of glucagon-like peptide-1--obesity, appetite, and stress: what is next? A review. Dig Dis Sci (2007) 0.84
Cancer initiation and progression: an unsimplifiable complexity. Theor Biol Med Model (2006) 0.84
Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy. J Immunother (2011) 0.84
Sperm protein 17 is expressed in the sperm fibrous sheath. J Transl Med (2009) 0.84
Is sperm protein 17 a useful target for tumor immunotherapy? Blood (2003) 0.84
Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability. Int Rev Immunol (2012) 0.84
Silibinin restores paclitaxel sensitivity to paclitaxel-resistant human ovarian carcinoma cells. Anticancer Res (2008) 0.83
Tracking human multiple myeloma xenografts in NOD-Rag-1/IL-2 receptor gamma chain-null mice with the novel biomarker AKAP-4. BMC Cancer (2011) 0.83
Mast cells and human hepatocellular carcinoma. World J Gastroenterol (2003) 0.83
Sperm protein 17 is a suitable target for adoptive T-cell-based immunotherapy in human ovarian cancer. J Immunother (2008) 0.83
Practical model for psychosocial care. J Oncol Pract (2009) 0.83
Modulation of p38 MAPK signaling enhances dendritic cell activation of human CD4+ Th17 responses to ovarian tumor antigen. Cancer Immunol Immunother (2013) 0.83
Heparin and carboxymethylchitosan metal nanoparticles: an evaluation of their cytotoxicity. Biomed Res Int (2013) 0.83
Cancer testis antigens: a novel target in lung cancer. Int Rev Immunol (2012) 0.83
A cost-benefit analysis of bariatric surgery on the South Plains region of Texas. Obes Surg (2011) 0.83
Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy. Int Rev Immunol (2015) 0.83
CDK1-mediated phosphorylation of Abi1 attenuates Bcr-Abl-induced F-actin assembly and tyrosine phosphorylation of WAVE complex during mitosis. J Biol Chem (2011) 0.82
Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol (2005) 0.82
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone [corrected] induces CRM1-dependent p53 nuclear accumulation in human bronchial epithelial cells. Toxicol Sci (2010) 0.82
Application of vitamin D and derivatives in hematological malignancies. Cancer Lett (2011) 0.82
Vascular architecture: is it a helpful histopathological biomarker for hepatocellular carcinoma? J Zhejiang Univ Sci B (2007) 0.82